SLE and Kidney Disease in 2014 GERALD APPEL, MD GERALD APPEL, MD Professor of Clinical Medicine Columbia University –College of Professor of Clinical Medicine.

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

Małgorzata Wągrowska-Danilewicz1, Marian Danilewicz2
Brown JR et al. Proc ASH 2013;Abstract 523.
Trial Design Issues in SLE Joel Schiffenbauer FDA/CDER DAAODP.
Lupus Nephritis. Background GM (G036181) 51 year old Caucasian female Presented with nephrotic syndrome and hypertension in 2000.
Cyclophosphamide vs Mycophenylate mofetil for lupus nephritis
Abetimus Sodium (LJP 394) a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene.
ISKDC. Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity.
Glomerular Diseases Dr. Atapour Differential diagnosis and evaluation of glomerular disease.
Proteinuria Outcome Lupus Nephritis Classes of Lupus Nephritis I.Minimal II.Mesangial III.Focal proliferative* IV.Diffuse proliferative* V.Membranous**
Case Presentation Dr Mohan Shenoy Consultant Paediatric Nephrologist Royal Manchester Children’s Hospital.
Treatment of Vasculitis: immunesuppressives and biologics
Case D 1 Age 37 M HIV for 17 years 1 week history of diarrhoea and fever Abrupt onset of oedema and oliguria Homosexual Teenage drug abuse.
R Bhimma Department of Paediatrics and Child Health
Lupus Nephritis in Children Renal involvement in SLE: 30% - 70% Renal involvement in SLE: 30% - 70% Most diagnosis in adolescence, rare < 5y/o Most diagnosis.
Mechanism and New. Lupus Erythematosus - Medication NSAIDs may be used for musculoskeletal and mild systemic complaints, although ibuprofen.
Lupus Nephritis Emily Chang April 13, The “Glom”
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Lupus glomerulonephritis. summary Etiology and pathogenesis Morphologic classification and clinical relevance Class switching in follow-up biopsies Alternative.
ROLE OF RENAL BIOPSY IN SILENT LUPUS NEPHRITIS M.E. Guerra 1, Y. Arce 2, M.M Díaz 3, P. Moya 4. J. Ballarín 3, F. Algaba 5 1 Department of Pathology. Central.
Proteinuria as a Surrogate Outcome in IgA Nephropathy Ron Hogg MD Scott & White Medical Center Temple, Texas.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
OBJECTIVES NOT TO BE A NEPHROLOGIST
U Lupus.Nephrotic syndrome now. Normal creat.  C3/C4, ANA +, ? Membranous ?antiphospholipid Ab syndrome.
Primary glomerular diseases Talia Weinstein MD PhD Sourasky Medical Center.
Proteinuria as a Surrogate in Kidney Disease In primary GN membranous nephropathy and focal and segmental glomerulosclerosis assocciated with the nephrotic.
Nephrotic Syndrome (NS)
U and U # U y.o. male ? Wegener’s.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
Severe vascular lesions and poor functional outcome
Treatment of LN An European perspective Frédéric A. HOUSSIAU Department of Rheumatology Cliniques universitaires Saint-Luc LOUVAIN Medical School XXXV.
Nephrotic Syndrome Etiology Idiopathic nephrotic syndrome (90%)
Interstitial nephritis associated with PostInfectious GN PRAET MARLEEN, MD, PhD UNIVERSITY HOSPITAL GHENT.
ISRTPCON 2013 Lt Col Rohit Tewari Dept of Pathology Armed Forces Medical College Pune.
U # y.o. female with pneumonia  creatinine proteinuria very low C3, C4.
WHO Classification of Lupus Nephritis
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
And Review of Acute nephritis Syndromes. Karyomegalic Tubulointerstitial Nephritis  Symptoms: Recurrent Pneumonias Renal failure leading invariably to.
Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Lonial.
Lupus Nephritis Prof. Hafiz Ijaz Ahmad Department of Nephrology Allama Iqbal Medical College Lahore.
Natalizumab- Unmet Need in the Management of Crohn’s Disease Doug Wolf, M.D. Atlanta Gastroenterology Associates July 31, 2007.
U # IgG- strong coarsely granular capillary loop staining,mild to moderate granular peritubular staining IgA- moderate mesangial staining.
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
U # yr old woman with Serum Cr 202 Urine Pr/Cr 338 mg/mmol,elevated LFTs Weight loss No hematuria SPEP-polyclonal gammopathy (L) Native.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Overview of Glomerulonephritidies
Recurrence of Henoch-Schonlein purpura nephritis after 6.5 years of remission- an unusual clinical occurrence Vignesh Pandiarajan*, Deepti Suri*, Anju.
Systemic lupus erythematous with lupus nephritis Diagnosis & Treatment
Lupus Nephritis. Introduction 60 – 75% of pts with SLE Probably the most serious complication Differs in clinical pattern, severity, prognosis & treatment.
Presenter:Dr. Mukesh Sharma Preceptor:Dr. Manish Soneja.
“Monitoring Systemic Lupus Erythematosus” Andres Quiceno, MD Presbyterian Hospital of Dallas.
Lupus Nephritis Update 2010
Geisler C et al. Proc ASH 2011;Abstract 290.
Palumbo A et al. Proc ASH 2012;Abstract 200.
Lupus Nephritis Treatment
“Systemic Lupus Erythematosus” Renal features
Renal disease in SLE R4 이설라/Prof.임천규.
IgA nephropathy 2014년 8월 6일 R1 황규환.
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
Mateos MV et al. Proc ASH 2013;Abstract 403.
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for.
Nat. Rev. Nephrol. doi: /nrneph
World Kidney Day 2016: Kidney Disease & Children
Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.
World Kidney Day 2016: Kidney Disease & Children
Current standard of care treatment protocols for LN induction therapy.
Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.
Presentation transcript:

SLE and Kidney Disease in 2014 GERALD APPEL, MD GERALD APPEL, MD Professor of Clinical Medicine Columbia University –College of Professor of Clinical Medicine Columbia University –College of Physicians and Surgeons Physicians and Surgeons NY-Presbyterian Hospital New York, New York NY-Presbyterian Hospital New York, New York

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

Where can one find a kidney?

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

ISN/RPS Classification of LN Class I Minimal mesangial LN Class II Mesangial proliferative LN Class III Focal LN III (A): Active lesions: focal proliferative LN III (A/C): Active and chronic lesions III (C): Chronic inactive lesions with scars Class IV Diffuse LN IV-S (A): Active lesions: diffuse segmental proliferative LN IV-G (A): Active lesions: diffuse global proliferative LN IV-S (A/C): Active and chronic lesions IV-G (A/C): Active and chronic lesions IV-S (C): Chronic inactive lesions with scars IV-G (C): Chronic inactive lesions with scars Class V Membranous LN Class VI Advanced sclerotic LN ISN = International Society of Nephrology; RPS = Renal Pathology Society

Lupus Nephritis Class I

Lupus Nephritis Class II

Lupus Nephritis Class III

Histology WHO Class IV: Diffuse Endocapillary Proliferation With Karyorrhexis and Focal Necrosis Focal NecrosisEndocapillary Proliferation

Lupus Nephritis Class IV Pre-Rx Post-Rx

Lupus Nephritis Class IV

Lupus Nephritis Class V

End stage kidney due to chronic GN: Diffuse and global glomerulosclerosis, tubular atrophy & interstitial fibrosis

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

Case 3: Saleswoman with rash and arthritis A 29 year old saleswoman develops arthritis multiple joints, fever Exam: Lymphadenopathy, and a malar rash. Labs: –Urinalysis 3+ protein, rbc’s –Creatinine 1.2 mg/dl –24 hr. protein 1.8 g per day –Complement 18% (normal %) –ANA positive, Anti-DNA antibody positive KIDNEY BIOPSY PERFORMED

RBC cast forms a mold of tubular lumen

Diffuse proliferative lupus nephritis: Diffuse and global mesangial and glomerular capillary wall positivity for IgG Full house IF staining: IgG, IgM, IgA, C3, C1q

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

EventCy Therapy (n = 21) Combination Therapy (n = 20) n/n Hypertension10/20 Ischemic heart disease1/194/19 Hyperlipidemia7/208/19 Valvular heart disease9/197/21 Avascular necrosis6/216/20 Osteoporosis4/183/19 Premature menopause9/1610/18 Major infections7/219/20 Herpes zoster infection6/215/20 Side Effects of Cyclophosphamide in the past

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

MMF + glucocorticoids (e.g. pulse methylprednisolone ) CYC + Glucocorticoids (e.g. pulse methylprednisolone) CYC + Glucocorticoids (e.g. pulse methylprednisolone) or EURO LUPUS Low-dose CYC EURO LUPUS Low-dose CYC NIH study Hi-dose CYC NIH study Hi-dose CYC or 6 months INDUCTION Proliferative LN ACR- KDIGO Treatment guidelines – CONFIDENTIAL Anti-MIF & LN Ad Board, July 13, 2011

Proliferative Lupus Nephritis – Maintenance Treatment ACR – KDIGO Treatment guidelines IMPROVED NOT IMPROVED MMF induction MMF induction MMF1-2g/d or AZA 2 mg/kg/d ± lo dose daily GC CYC (lo- or hi- dose) + pulse GC then daily GC CYC (lo- or hi- dose) + pulse GC then daily GC 6 months CYC induction CYC induction IMPROVED NOT IMPROVED MMF1-2g/d or AZA 2 mg/kg/d ± lo dose daily GC MMF 2-3g/d x 6 months + pulse GC then daily GC MMF 2-3g/d x 6 months + pulse GC then daily GC 6 months

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

ELNT - 10 year FU - ESRD Houssiau FA et al. Ann Rheum Dis 2009,

ELNT - 10 year FU Houssiau FA et al. Ann Rheum Dis 2009, Jan 20 (Epub ahead of print)

ALMS TRIAL Primary Endpoint: Responders at Month 6 Response judged by blinded Clinical Endpoint Committee: Decrease in proteinuria to <3g if baseline nephrotic (≥3g/d), or by ≥50% in patients ith subnephrotic (<3g/d) proteinuria and Stabilization of serum creatinine level (24-week level ± 25% of baseline), or improvement MMF was not superior to IVC (p = 0.575) MMF IVC Appel, Contreras, Dooley et al JASN 2009

IVC MMF ALMS Trial - Renal Variables Serum creatinine and urine protein levels improved in both the MMF and IVC groups

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.

Rituximab: Anti-CD20 Monoclonal Antibody Rituximab - FDA approved for the treatment of relapsed or refractory, CD20-positive B-cell NHLymphomas Approved for Rheumatoid Arthritis – used in 240,000 patients > 10 yrs Approved for ANCA+ glomerulonephritis since 2010 Chimeric murine/human monoclonal antibody Davies B, Shaw T. Presented at EULAR Maloney DG, et al. J Clin Oncol. 1997;15(10):

Rituxilup Trial MPred + MMF + Rituximab vs MP + MMF + steroids ( ALMS regimen ) 19 Adult + 4 Peds Centers in UK; Europe 12 Centers in 3 networks; US Centers. Non-inferiority Trial of 252 LN patients Primary endpoint complete remission at 1 yr. Secondary Endpoints – Time to CR, Partial remissions, PR with histologic response, serious infections, SAEs, SRI score etc.

Navarra, et al. Lancet. 2011;377(9767): Furie, et al. Arthritis Rheum. 2011;63(12): mg/kg belimumab Visit Week SRI Responders (%) +++ * + * + * + * + * + * + * * p< p< mg/kg belimumab Placebo Visit Week % SRI Responders * Belimumab – FDA Approved for SLE p<0.05 SRI, SLE Responder Index IMNL-SCT

Abatacept ( CTLA4Ig Co-Stimulatory Blocker ) Study in 300 LN PTS Background Rx: MMF up to 3 g/day plus corticosteroids Primary Outcome Measure: Time to complete response Abatacept 10/10 10 mg/kg days 1,15, 29, then Q 28 days Abatacept 10/10 10 mg/kg days 1,15, 29, then Q 28 days Abatacept 30/10 30 mg/kg x4, then 10 mg/kg Q 28 days Abatacept 30/10 30 mg/kg x4, then 10 mg/kg Q 28 days Placebo Days 1 and 15 (1 st and 2 nd dose) Day 337 Final dose Dose every 28 days Randomization 1:1:1 Courtesy of D Wofsy

Brad H. Rovin on behalf of the ACCESS Trial Group Treatment of LN with Abatacept and Low- Dose Pulse Cyclophosphamide: The ACCESS Trial Brad H. Rovin on behalf of the ACCESS Trial Group EuroLupus Low dose Cyclophosphamide and prednisone starting at 60 mg (tapering to 10 mg by week 12 ) Azathioprine 2 mg/kg/day PO maintenance Abatacept 500 mg or 1000 mg at 0, 2, 4, then Q4 wk until week 24 vs Placebo

Proteasome Inhibitors N H H NB O OH OH O N N Bortezomib ™) ( Velcade™) Carfilzomib (Kyprolis) ManufacturerTakedaOnyx/Amgen StatusApproved Indications Myeloma & Mantle Cell Lymphoma Myeloma & Solid Tumors ClassBoronic AcidKetoepoxide Active Sites Targeted  5/LMP7/LMP2  5/LMP7

Bortezomib for NZB/W F1: Kidney Disease Neubert Nat. Med. 2008

An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients with Membranous (Class V) Lupus Nephritis Principal Investigator: Brad H. Rovin MD, Ohio State University SCRN Study Month  ARM 1. Acthar Gel 80 IU administered subcutaneously 2 times per week, 12 patients  ARM 2. Acthar Gel 80 IU administered subcutaneously 3 times per week, 13 patients Administration of ActharFollow-Up Primary Objectives: To determine the safety and tolerability of Acthar Gel in patients with Class V lupus nephritis To determine the efficacy of Acthar Gel in patients with Class V lupus nephritis as CRR+PRR

Treatment of Severe LN in the Future Treatment will still be divided into an induction and maintenance phase. Induction therapy will consist of Cyclophosphamide (usually IV ) or MMF or Newer regimens e.g. older drugs combined with CNI’s, ACTH, proteosome inhibitors, or corticosteroid free Rituximab regimens. Maintenance therapy will consist of MMF or AZA or rituximab or other newer agents. Use of combinations of immunosuppressives will increase. One Regimen Will Not Fit All

Lupus and Kidney Disease What are the kidneys – how do they work? ( what is a nephrologist?) How does SLE involve the kidneys? How do you know if you have kidney involvement? Are there different patterns of Kidney disease with SLE? What happened with SLE Kidney disease ( lupus nephritis )in the past ? Can we treat kidney disease due to LN today? How successful are we? Will there be new ways to treat it tomorrow.